0001767398-24-000003.txt : 20240311
0001767398-24-000003.hdr.sgml : 20240311
20240311132503
ACCESSION NUMBER: 0001767398-24-000003
CONFORMED SUBMISSION TYPE: D/A
PUBLIC DOCUMENT COUNT: 1
ITEM INFORMATION: 06b
FILED AS OF DATE: 20240311
DATE AS OF CHANGE: 20240311
EFFECTIVENESS DATE: 20240311
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: Melt Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001767398
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 611888986
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: D/A
SEC ACT: 1933 Act
SEC FILE NUMBER: 021-489452
FILM NUMBER: 24737365
BUSINESS ADDRESS:
STREET 1: 5511 VIRGINIA WAY
STREET 2: SUITE 300
CITY: BRENTWOOD
STATE: TN
ZIP: 37027
BUSINESS PHONE: 8587044042
MAIL ADDRESS:
STREET 1: 5511 VIRGINIA WAY
STREET 2: SUITE 300
CITY: BRENTWOOD
STATE: TN
ZIP: 37027
D/A
1
primary_doc.xml
X0708
D/A
LIVE
0001767398
Melt Pharmaceuticals, Inc.
5511 VIRGINIA WAY
SUITE 300
BRENTWOOD
TN
TENNESSEE
37027
(629) 802-9555
DELAWARE
None
None
Corporation
true
2019
Larry
Dillaha
5511 Virginia Way
Suite 300
Brentwood
TN
TENNESSEE
37027
Executive Officer
Director
Brad
Osborne
5511 Virginia Way
Suite 300
Brentwood
TN
TENNESSEE
37027
Executive Officer
Pharmaceuticals
Decline to Disclose
- 06b
true
0001767398-24-000002
2023-07-28
false
true
false
0
Newbridge Securities Corporation
None
None
None
1200 North Federal Highway
Suite 400
Boca Raton
FL
FLORIDA
33432
AL
ALABAMA
AZ
ARIZONA
AR
ARKANSAS
CA
CALIFORNIA
CO
COLORADO
CT
CONNECTICUT
DE
DELAWARE
FL
FLORIDA
GA
GEORGIA
IL
ILLINOIS
KY
KENTUCKY
MD
MARYLAND
MA
MASSACHUSETTS
MI
MICHIGAN
MN
MINNESOTA
MO
MISSOURI
NJ
NEW JERSEY
NY
NEW YORK
NC
NORTH CAROLINA
OH
OHIO
OK
OKLAHOMA
PA
PENNSYLVANIA
TN
TENNESSEE
TX
TEXAS
UT
UTAH
VA
VIRGINIA
WA
WASHINGTON
WI
WISCONSIN
false
47763600
41552780
6210820
The Total Offering Amount was increased to account for the issuance of securities to settle certain outstanding indebtedness.
false
300
1736850
0
In addition to the Sales Commissions noted above, the placement agent may recieve compensation warrants to purchase up to a maximum of 105,882 shares.
0
true
false
Melt Pharmaceuticals, Inc.
/s/ Brad Osborne
Brad Osborne
Chief Financial Officer
2024-03-11